Literature DB >> 7901917

Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy.

M B Abelson1, K Schaefer.   

Abstract

The pathogenesis of ocular allergy involves multiple mechanisms, which lead to mast cell degranulation and the release of chemical mediators. Mast cell mediators that have been implicated in allergic ocular disease include histamine, eosinophil chemotactic factors, eosinophil granule major basic protein, platelet-activating factor, prostaglandin D2, and several other less well-defined preformed or newly synthesized mediators. The release of these chemical mediators ultimately results in conjunctival vasodilation, increased vascular permeability, leukocyte chemotaxis, and, rarely, ocular surface destruction. Current therapy of ocular allergy involves elimination of the offending allergen, modulation of the immune system, and pharmacologic inhibition of the chemical mediators. The purpose of this article is to provide a better understanding of the pathogenesis and current therapy of ocular allergic disorders and to review the central role of the mast cell and chemical mediators involved in ocular allergy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901917     DOI: 10.1016/0039-6257(93)90036-7

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  31 in total

1.  Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily.

Authors:  K A Larson; E V Olson; B J Madden; G J Gleich; N A Lee; J J Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 2.  Allergic eye disease mechanisms.

Authors:  J I McGill; S T Holgate; M K Church; D F Anderson; A Bacon
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

Review 3.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

4.  Conjunctival and Intrascleral Vasculatures Assessed Using Anterior Segment Optical Coherence Tomography Angiography in Normal Eyes.

Authors:  Tadamichi Akagi; Akihito Uji; Alex S Huang; Robert N Weinreb; Tatsuya Yamada; Manabu Miyata; Takanori Kameda; Hanako Ohashi Ikeda; Akitaka Tsujikawa
Journal:  Am J Ophthalmol       Date:  2018-08-09       Impact factor: 5.258

5.  Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis.

Authors:  Gennaro D'Angelo; Alessandro Lambiase; Magdalena Cortes; Roberto Sgrulletta; Roberta Pasqualetti; Ambra Lamagna; Stefano Bonini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-15       Impact factor: 3.117

Review 6.  Dry eye disease and microbial keratitis: is there a connection?

Authors:  Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott
Journal:  Ocul Surf       Date:  2013-01-29       Impact factor: 5.033

7.  Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus.

Authors:  B Mortemousque; A Jacquet; C Richard; F Depont; J Colin; N Moore
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

8.  Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies.

Authors:  Arthur B Epstein; Peter T Van Hoven; Alan Kaufman; Warner W Carr
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis.

Authors:  M Kidd; S H McKenzie; I Steven; C Cooper; R Lanz
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

10.  Human conjunctival epithelial cell responses to platelet-activating factor (PAF): signal transduction and release of proinflammatory cytokines.

Authors:  Najam A Sharif; Shouxi Xu; Peggy E Hellberg; Iok-Hou Pang; Daniel A Gamache; John M Yanni
Journal:  Mol Vis       Date:  2009-06-06       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.